NCT03153488

Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response

Status unknown NA Last updated 26 September 2022

What this trial tests

NA trial testing MRI in Attention Deficit Hyperactivity Disorder in 60 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
1 July 2023

1 December 2023

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 July 2018
Primary completion	1 July 2023
Estimated completion	1 December 2023
Sites	1 location across United States

Drugs / interventions tested

• MRI — full drug profile →

Conditions studied

• Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 55, any sex, with Attention Deficit Hyperactivity Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 6-month trial in adults to find out if certain neuromarkers can predict individual treatment response to stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD). Males and females, ages 18-45, will complete an MRI scan at MIT prior to beginning medication for ADHD as determined by a treating clinician outside the context of this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
   Castells X, Blanco-Silvente L, Cunill R. · · 2018 · cited 66× · PMID 30091808 · DOI 10.1002/14651858.cd007813.pub3